Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Welsh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Arizona College of Medicine-TucsonResidency, Radiation Oncology, 2004 - 2008
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalInternship, Internal Medicine, 2003 - 2004
Geisel School of Medicine at DartmouthClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2008 - 2025
OK State Medical License 2020 - 2021
American Board of Radiology Radiation Oncology
Clinical Trials
- Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer Start of enrollment: 2009 Mar 26
- Simultaneous Integrated Boost (SIB) in Esophageal Cancer Start of enrollment: 2010 Apr 01
- Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7immunorad conference.Pierre-Antoine Laurent, Fabrice André, Alexandre Bobard, Desiree Deandreis, Sandra Demaria
Oncoimmunology. 2025-12-01 - Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum
The Lancet. Oncology. 2025-03-01 - Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins.Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu
Molecular Cancer. 2025-02-03
Press Mentions
Nanobiotix Announces First Data from the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients with Locally Advanced NSCLCMarch 27th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
